Cargando…

The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials

BACKGROUND: Historically, data on the rate of hyperglycemia and ketosis have not been collected in clinical trials. However, it is clinically important to assess the rate of these events in children with type 1 diabetes (T1D). This question was addressed in two pediatric trials using insulin deglude...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thalange, Nandu, Deeb, Larry, Klingensmith, Georgeanna, Franco, Denise R., Bardtrum, Lars, Tutkunkardas, Deniz, Danne, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons A/S 2019
Materias:	Clinical Care and Technology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849556/ https://www.ncbi.nlm.nih.gov/pubmed/30666772 http://dx.doi.org/10.1111/pedi.12821

Ejemplares similares

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK
por: Thalange, Nandu, et al.
Publicado: (2019)

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
por: Thalange, Nandu, et al.
Publicado: (2015)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
por: Thalange, Nandu, et al.
Publicado: (2016)

Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports
por: Thalange, Nandu, et al.
Publicado: (2019)

Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK
por: Thalange, Nandu, et al.
Publicado: (2017)

The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes
por: Haluzík, Martin, et al.
Publicado: (2018)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
por: Haahr, Hanne, et al.
Publicado: (2016)

Weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?
por: Russell‐Jones, D., et al.
Publicado: (2015)

The association between anti‐insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast‐acting insulin aspart in children and adolescents with type 1 diabetes
por: Biester, Torben, et al.
Publicado: (2020)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients
por: Ikushima, Ippei, et al.
Publicado: (2015)

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK
por: Pollock, Richard F., et al.
Publicado: (2018)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Diabetic Ketosis Caused by the Insulin Analog Aspart–Induced Anti-Insulin Antibody: Successful Treatment With the Newest Insulin Analog Glulisine
por: Yanai, Hidekatsu, et al.
Publicado: (2011)

Reduced Efficacy of Insulin Detemir in Controlling Hyperglycemia during Pregnancy: An Interesting Case Report
por: Pande, Arun, et al.
Publicado: (2018)

The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2020)

Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
por: Pieber, Thomas R., et al.
Publicado: (2020)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
por: Pollock, Richard F., et al.
Publicado: (2019)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Comparing the efficacy and safety of insulin detemir versus neutral protamine hagedorn insulin in treatment of diabetes during pregnancy: a randomized, controlled study
por: ji, Jing, et al.
Publicado: (2020)

Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis
por: Buckingham, Bruce A., et al.
Publicado: (2015)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-To-Target Trial (ADAPT)
por: Le Floch, Jean-Pierre, et al.
Publicado: (2009)

Efficacy and Safety of Insulin Degludec for Hyperglycemia Management in Noncritical Hospitalized Patients with Diabetes: An Observational Study
por: Simioni, Natalino, et al.
Publicado: (2017)

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)
por: Hirsch, I. B., et al.
Publicado: (2016)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension
por: Mathieu, Chantal, et al.
Publicado: (2013)

Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes
por: Lane, Wendy, et al.
Publicado: (2021)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice
por: Sesti, Giorgio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b0pq35kqjg2qcpe62ldm123mto